Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kiniksa Pharmaceuticals Ltd.

28.04
-0.4500-1.58%
Post-market: 28.00-0.0400-0.14%17:50 EDT
Volume:8.69M
Turnover:243.78M
Market Cap:2.05B
PE:-118.99
High:28.86
Open:28.50
Low:27.91
Close:28.49
Loading ...

Eben Tessari, Chief Operating Officer, Reports Disposal of Kiniksa Pharmaceuticals Common Shares

Reuters
·
19 Jun

Eben Tessari, COO, Reports Disposal of Common Shares of Kiniksa Pharmaceuticals International plc

Reuters
·
12 Jun

Mark Ragosa, CFO of Kiniksa Pharmaceuticals, Reports Disposal of Common Shares

Reuters
·
06 Jun

BRIEF-Kiniksa Pharmaceuticals Announces Trial Design Of Planned Phase 2/3 Clinical Trial Of Kpl-387 In Recurrent Pericarditis

Reuters
·
05 Jun

Kiniksa Pharmaceuticals International Plc - to Initiate Phase 2/3 Trial of Kpl-387 in Mid-2025

THOMSON REUTERS
·
05 Jun

Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of Kpl-387 in Recurrent Pericarditis

THOMSON REUTERS
·
05 Jun

Kiniksa Pharmaceuticals International Plc: Kpl-387 Phase 2 Data Expected in 2H 2026

THOMSON REUTERS
·
05 Jun

Kiniksa Pharmaceuticals International plc Conducted Annual Shareholders Meeting

Reuters
·
04 Jun

Chairman & CEO Sanj K. Patel Reports Disposal of Common Shares of Kiniksa Pharmaceuticals International plc

Reuters
·
29 May

Chairman & CEO Sanj K. Patel Reports Disposal of Kiniksa Pharmaceuticals Common Shares

Reuters
·
23 May

Eben Tessari, COO, Reports Disposal of Common Shares in Kiniksa Pharmaceuticals International plc

Reuters
·
22 May

Chairman & CEO Sanj K. Patel Reports Disposal of Common Shares of Kiniksa Pharmaceuticals International plc

Reuters
·
16 May

Kiniksa Pharmaceuticals (KNSA) Receives a Buy from Evercore ISI

TIPRANKS
·
13 May

Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis

GlobeNewswire
·
30 Apr

An Intrinsic Calculation For Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Suggests It's 41% Undervalued

Simply Wall St.
·
30 Apr

Kiniksa Pharmaceuticals Is Maintained at Buy by Jefferies

Dow Jones
·
30 Apr

Wedbush Raises Price Target on Kiniksa Pharmaceuticals to $36 From $34, Maintains Outperform Rating

MT Newswires Live
·
30 Apr

Honeywell Posts Better-Than-Expected Q1 Earnings, Joins Crown Holdings, Noble, Crane And Other Big Stocks Moving Higher On Tuesday

Benzinga
·
29 Apr

Kiniksa Pharmaceuticals Swings to Q1 Net Income, Revenue Increases

MT Newswires Live
·
29 Apr

Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q1 Earnings and Revenue Estimates

Zacks
·
29 Apr